Cadila Healthcare gets FDA nod for phase 2(b)/3 trial of saroglitazar magnesium

TAGS

Cadila Healthcare (Zydus Cadilla) said that it has obtained permission from the US Food and Drug Administration (FDA) to launch the phase 2(b)/3 clinical trial of saroglitazar magnesium in primary biliary cholangitis (PBC).

The late-stage trial, designed to assess the efficacy and safety of saroglitazar magnesium, will have 192 patients. The participants will be randomly grouped in a 1:1:1 ratio to receive Saroglitazar 1 mg or Saroglitazar 2 mg or placebo.

See also  Ineos breaks ground on new acrylonitrile styrene acrylate plant in Bayport

The clinical trial will study saroglitazar magnesium (1 or 2 mg) in comparison to placebo based on the composite endpoints — Alkaline Phosphatase (ALP), liver stiffness measurement (LSM) by FibroScan, total bilirubin, liver enzyme parameters, lipid parameters, health related quality of life using PBC 40 questionnaire and other outcome measures over a 52-week period.

Cadila Healthcare gets FDA nod for phase 2(b)/3 trial of saroglitazar magnesium

Cadila Healthcare gets FDA nod for phase 2(b)/3 trial of saroglitazar magnesium. Photo courtesy of Zydus Cadila.

Pankaj R. Patel — chairman of Cadila Healthcare said: “Primary Biliary Cholangitis (PBC) is a severe liver disease leading to cirrhosis of the liver, liver failure, and possibly death. PBC patients have limited treatment options and approximately 50% of the PBC patients are not able to benefit from the existing therapy due to lack of response or intolerable side effects.

See also  Air Products to build new liquid hydrogen plant at La Porte, Texas

“Based on the positive results from our earlier Phase 2 study, we have now initiated the pivotal EPICS III trial in both cirrhotic and non-cirrhotic PBC patients.”

Saroglitazar magnesium is an investigational compound that has orphan drug designation and fast track designation in the US for primary biliary cholangitis.

CATEGORIES
TAGS
Share This